Sampson et al 1 are to be congratulated for their important contribution to knowledge of the effects of gender on the effects of angiotensin peptides. Importantly, their study showed in rats that low-dose angiotensin II reduced blood pressure in females but not in males, and this blood pressure reduction was mediated by the angiotensin II type 2 receptor. Moreover, high-dose angiotensin II produced a lesser increase in blood pressure in female than in male rats.
Can the Study of Female Rats Help Our
Understanding of Women?
To the Editor: Sampson et al 1 are to be congratulated for their important contribution to knowledge of the effects of gender on the effects of angiotensin peptides. Importantly, their study showed in rats that low-dose angiotensin II reduced blood pressure in females but not in males, and this blood pressure reduction was mediated by the angiotensin II type 2 receptor. Moreover, high-dose angiotensin II produced a lesser increase in blood pressure in female than in male rats.
These data have important and far-reaching clinical implications. First, therapies that reduce angiotensin II levels, such as angiotensin-converting enzyme inhibitors, renin inhibitors, and ␤-blockers, may be less effective in blood pressure reduction in women than in men and may even increase blood pressure in women by removing the angiotensin II-dependent, angiotensin II type 2 receptor-mediated depressor mechanism in women. Second, angiotensin receptor blocker therapies, by causing a reactive increase in angiotensin II levels, may increase angiotensin II type 2 receptor stimulation and thereby more effectively reduce blood pressure in women than in men.
In the introduction to their article, Sampson et al 1 argued the clinical justification for their study. It is, therefore, incumbent on the authors 1 and the editorialists 2 to address the clinical implications of these data 1 and to suggest reasons why clinical studies failed to show differences between men and women in their blood pressure responses to angiotensin-converting enzyme inhibitor, ␤-blocker, and angiotensin receptor blocker therapies. 3, 4 Moreover, men and women showed similar changes in blood pressure, effective renal plasma flow, and renal vascular resistance, in response to angiotensin II infusion, although women showed a decrease in glomerular filtration rate not seen in men. 5 Is it possible that the mechanisms described by Sampson et al 1 
